Acute Ischemic Stroke AIS Clinical Trial
Official title:
Stroke Imaging Package Study of Intracranial Atherosclerosis
A prospective, multicenter, cohort study to explore the stroke mechanisms of symptomatic intracranial atherosclerosis, the dynamic changes under aggressive medical treatment and their associations with clinical events using conventional MRI sequences plus high-resolution magnetic resonance (HR-MRI).
1. First-ever stroke patients attributed to intracranial artery stenosis (> 50% or
occlusion) within 7 days after onset will be prospectively enrolled in our study and
undergo new imaging technique package assessment at baseline.
2. The imaging technique package includes conventional cranial MRI (T1,T2,T2 FLAIR,DWI),
cranial magnetic resonance angiography (MRA),high-resolution magnetic resonance (HR-MRI)
and susceptibility weighted imaging (SWI) or T2*-weighted imaging.
3. Enrolled patients are recommended to receive aggressive medical management consisted of
Aspirin (100 mg daily) and Clopidogrel (75 mg daily) for 3 months and Rosuvastatin (20mg
daily) for at least 6 months as well as traditional risk factors management.
4. Patients were followed up for mRS score, stroke recurrence, medication compliance and
laboratory examination including blood routine tests, liver functions and creatine
kinase et al at 3 months, 6 months and 12 months after stroke onset. Additionally,
patients are required to retake new HRMRI imaging of brain at 6 months.Remote patient
education by We-Chat will be performed.
5. Our study aims to explore the stroke mechanisms of symptomatic intracranial
atherosclerosis, the dynamic changes under aggressive medical treatment and their
associations with clinical events using conventional MRI sequences plus HR-MRI.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052969 -
Pulse Endovascular ReperFUSION for Acute Ischemic Stroke
|
N/A | |
Not yet recruiting |
NCT06320431 -
ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
|
Phase 3 |